Takeda Pharmaceutical Co. Ltd. Reports Findings in Fabry Disease (Long-term safety of enzyme replacement therapy with agalsidase alfa in patients with Fabry disease: post-marketing extension surveillance in Japan)

Source :: Marketing Weekly News. August 17, 2024, 102
Publication Year :: 2024
Abstract: 2024 AUG 17 (VerticalNews) -- By a News Reporter-Staff News Editor at Marketing Weekly News -- New research on Nutritional and Metabolic Diseases and Conditions - Fabry Disease is the [...]

Subjects :: Takeda Pharmaceutical Company Ltd. -- Reports
Medical research -- Reports
Medicine, Experimental -- Reports
Biopharmaceutics -- Reports
Diseases -- Drug therapy -- Japan
Enzymes -- Reports
Marketing -- Reports
Pharmaceutical industry -- Reports
Advertising, marketing and public relations

Tools